248 related articles for article (PubMed ID: 24958095)
1. Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab.
Rahman R; Hempfling K; Norden AD; Reardon DA; Nayak L; Rinne ML; Beroukhim R; Doherty L; Ruland S; Rai A; Rifenburg J; LaFrankie D; Alexander BM; Huang RY; Wen PY; Lee EQ
Neuro Oncol; 2014 Nov; 16(11):1523-9. PubMed ID: 24958095
[TBL] [Abstract][Full Text] [Related]
2. [Retrospective analysis of 24 recurrent glioblastoma after chemoradiation and treated with nitrosoureas or irinotecan and bevacizumab].
Vauleon E; Mesbah H; Gedouin D; Lecouillard I; Louvel G; Hamlat A; Riffaud L; Carsin B; Quillien V; Audrain O; Lesimple T
Bull Cancer; 2012 Feb; 99(2):121-6. PubMed ID: 22257744
[TBL] [Abstract][Full Text] [Related]
3. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
Taal W; Oosterkamp HM; Walenkamp AM; Dubbink HJ; Beerepoot LV; Hanse MC; Buter J; Honkoop AH; Boerman D; de Vos FY; Dinjens WN; Enting RH; Taphoorn MJ; van den Berkmortel FW; Jansen RL; Brandsma D; Bromberg JE; van Heuvel I; Vernhout RM; van der Holt B; van den Bent MJ
Lancet Oncol; 2014 Aug; 15(9):943-53. PubMed ID: 25035291
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial.
Beije N; Kraan J; Taal W; van der Holt B; Oosterkamp HM; Walenkamp AM; Beerepoot L; Hanse M; van Linde ME; Otten A; Vernhout RM; de Vos FY; Gratama JW; Sleijfer S; van den Bent MJ
Br J Cancer; 2015 Jul; 113(2):226-31. PubMed ID: 26042933
[TBL] [Abstract][Full Text] [Related]
5. Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine.
Heiland DH; Masalha W; Franco P; Machein MR; Weyerbrock A
J Neurooncol; 2016 Feb; 126(3):567-75. PubMed ID: 26614518
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.
Lassen U; Sorensen M; Gaziel TB; Hasselbalch B; Poulsen HS
Anticancer Res; 2013 Apr; 33(4):1657-60. PubMed ID: 23564811
[TBL] [Abstract][Full Text] [Related]
7. Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients.
Jakobsen JN; Urup T; Grunnet K; Toft A; Johansen MD; Poulsen SH; Christensen IJ; Muhic A; Poulsen HS
J Neurooncol; 2018 Apr; 137(2):439-446. PubMed ID: 29330749
[TBL] [Abstract][Full Text] [Related]
8. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Brandes AA; Tosoni A; Basso U; Reni M; Valduga F; Monfardini S; Amistà P; Nicolardi L; Sotti G; Ermani M
J Clin Oncol; 2004 Dec; 22(23):4779-86. PubMed ID: 15570079
[TBL] [Abstract][Full Text] [Related]
9. Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab.
Quant EC; Norden AD; Drappatz J; Muzikansky A; Doherty L; Lafrankie D; Ciampa A; Kesari S; Wen PY
Neuro Oncol; 2009 Oct; 11(5):550-5. PubMed ID: 19332770
[TBL] [Abstract][Full Text] [Related]
10. Towards optimizing the sequence of bevacizumab and nitrosoureas in recurrent malignant glioma.
Wiestler B; Radbruch A; Osswald M; Combs SE; Jungk C; Winkler F; Bendszus M; Unterberg A; Platten M; Wick W; Wick A
J Neurooncol; 2014 Mar; 117(1):85-92. PubMed ID: 24458956
[TBL] [Abstract][Full Text] [Related]
11. A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy.
Møller S; Grunnet K; Hansen S; Schultz H; Holmberg M; Sorensen M; Poulsen HS; Lassen U
Acta Oncol; 2012 Jul; 51(6):797-804. PubMed ID: 22548369
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of toxicity of carmustine with or without bevacizumab in patients with recurrent or progressive high grade gliomas.
Yerram P; Reiss SN; Modelevsky L; Gavrilovic IT; Kaley T
J Neurooncol; 2019 Oct; 145(1):57-63. PubMed ID: 31432377
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab and daily temozolomide for recurrent glioblastoma.
Desjardins A; Reardon DA; Coan A; Marcello J; Herndon JE; Bailey L; Peters KB; Friedman HS; Vredenburgh JJ
Cancer; 2012 Mar; 118(5):1302-12. PubMed ID: 21792866
[TBL] [Abstract][Full Text] [Related]
14. A comprehensive analysis of factors related to carmustine/bevacizumab response in recurrent glioblastoma.
Cardona AF; Rojas L; Wills B; Ruiz-Patiño A; Abril L; Hakim F; Jiménez E; Useche N; Bermúdez S; Mejía JA; Ramón JF; Carranza H; Vargas C; Otero J; Archila P; Rodríguez J; Rodríguez J; Behaine J; González D; Jacobo J; Cifuentes H; Feo O; Penagos P; Pineda D; Ricaurte L; Pino LE; Vargas C; Marquez JC; Mantilla MI; Ortiz LD; Balaña C; Rosell R; Zatarain-Barrón ZL; Arrieta O
Clin Transl Oncol; 2019 Oct; 21(10):1364-1373. PubMed ID: 30798512
[TBL] [Abstract][Full Text] [Related]
15. Single-agent bevacizumab is an effective treatment in recurrent glioblastoma.
Hacibekiroglu I; Kodaz H; Erdogan B; Turkmen E; Ozcelik M; Esenkaya A; Saygi HM; Uzunoglu S; Cicin I
Med Oncol; 2015 Feb; 32(2):460. PubMed ID: 25572814
[TBL] [Abstract][Full Text] [Related]
16. Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma.
Walbert T; Gilbert MR; Groves MD; Puduvalli VK; Yung WK; Conrad CA; Bobustuc GC; Colman H; Hsu SH; Bekele BN; Qiao W; Levin VA
J Neurooncol; 2011 Apr; 102(2):273-80. PubMed ID: 20652724
[TBL] [Abstract][Full Text] [Related]
17. Addition of lomustine for bevacizumab-refractory recurrent glioblastoma.
Tonder M; Eisele G; Weiss T; Hofer S; Seystahl K; Valavanis A; Stupp R; Weller M; Roth P
Acta Oncol; 2014 Oct; 53(10):1436-40. PubMed ID: 24862539
[No Abstract] [Full Text] [Related]
18. Bevacizumab is active as a single agent against recurrent malignant gliomas.
Agha CA; Ibrahim S; Hassan A; Elias DA; Fathallah-Shaykh HM
Anticancer Res; 2010 Feb; 30(2):609-11. PubMed ID: 20332478
[TBL] [Abstract][Full Text] [Related]
19. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma.
Iwamoto FM; Abrey LE; Beal K; Gutin PH; Rosenblum MK; Reuter VE; DeAngelis LM; Lassman AB
Neurology; 2009 Oct; 73(15):1200-6. PubMed ID: 19822869
[TBL] [Abstract][Full Text] [Related]
20. Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer?
Backes FJ; Richardson DL; McCann GA; Smith B; Salani R; Eisenhauer EL; Fowler JM; Copeland LJ; Cohn DE; O'Malley DM
Int J Gynecol Cancer; 2013 Jun; 23(5):833-8. PubMed ID: 23640292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
